Navigation Links
Advanced Bionics Reaches Resolution With FDA, Settles Financial Suit
Date:7/18/2008

VALENCIA, Calif., July 18 /PRNewswire/ -- Advanced Bionics agreed to settle an administrative complaint arising from a disagreement with the U.S. Food and Drug Administration (FDA). The FDA asserted that Advanced Bionics should have made a formal submission five years ago before using a second vendor for a particular component in its cochlear implant system. The component, called a feedthru, contained a hidden weakness that allowed a very slow leak of water molecules into the implanted devices containing this vendor's feedthrus while blocking the passage of much smaller helium and nitrogen gases. Until this situation, such a condition was universally believed to be impossible. After an extended period of one year or more, the slow leakage led to device failures, a product recall, and a termination of the second vendor.

Advanced Bionics responded to FDA's complaint asserting the following: (1) it had tested the component with state-of-the-art processes and equipment, which demonstrated that gas molecules much smaller than water molecules were completely blocked from passage; (2) until this hidden weakness was observed, the industry standard testing was considered sufficient to ensure hermeticity; (3) the FDA's own experts in late 2004 mistakenly diagnosed the failure mechanism of the devices containing moisture; (4) Advanced Bionics followed the FDA's guidelines regarding filings with the FDA; and (5) the FDA's approval to market Advanced Bionics' HiRes90K Implantable Cochlear Stimulator was based upon a recognition that the HiRes90K was a repackaging of the previous generation device called CII that used feedthrus from both vendors.

Although the FDA did not accept these arguments, Advanced Bionics believes them to be true and denies that it violated the law. Nevertheless, rather than continuing a protracted and costly legal process that would likely harm its relationship with the FDA, Advanced Bionics has decided to settle this issue and move on.

In doing so, Advanced Bionics has agreed to pay the FDA $1.1 million and the chief executive officer has agreed to pay $75,000.

Founded in 1993 by Alfred Mann, Advanced Bionics is an innovative manufacturer of auditory technologies. Headquartered in Valencia, California, the company is the leading American manufacturer of cochlear implants -- the only technology approved by the FDA to functionally restore a human sense. To learn more about cochlear implants or for additional information, visit http://www.BionicEar.com or call 800.678.2575.


'/>"/>
SOURCE Advanced Bionics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
2. Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy
3. Advanced Life Sciences Announces Collaboration With UK Ministry of Defence on ALS-886
4. U.S. Genomics Awarded $9.1 Million Contract for Development of Advanced Biosensor by the U.S. Department of Homeland Security
5. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
6. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
7. Advanced Life Sciences Added to Russell Microcap Index
8. Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home
9. SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles
10. ABT is the Only Source for Kelo-cote(R) Advanced Formula Scar Gel
11. SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots , the leading ... the world, was today awarded the "Best Science & Technology Social Networking Service ... and decided upon by a dedicated team of researchers and analysts. , The ...
(Date:1/19/2017)... Jan. 18, 2017 The global biotechnology ... 92.9 billion by 2025, according to a new ... has been adaptive of the function of outsourcing ... 2002. Among the services outsourced, clinical trial management ... Johnson & Johnson was the first pharmaceutical company ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and ... announced today that it will host a live webcast of its ... p.m. (ET). The webcast can be accessed from ... for replay through Tuesday, January 31, 2017. ... About BD BD is a ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
Breaking Biology Technology:
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):